1 efficacy and safety of switching from boosted lopinavir (lpv/r) to boosted atazanavir (atv/r) in...
TRANSCRIPT
1
Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir
(ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The
ATAZIP study
Mallolas J.1, Podzamczer D.2, Domingo P.3, Clotet B.4, Ribera E.5, Gutierrez F.6, Knobel H.7, Cosin J.8, Ferrer E.2, Arranz J.A.9, Roca V.10, Vidal F.13,
Murillas J.14, Pedrol E.15, Llibre J.M.16, Dalmau D.17, Garcia I.18, Aranda M.19, Pich J.11, de Lazzari E.12, Gatell J.M.1, for the ATAZIP study group
1Hospital Clinic Universitari, Infectious Diseases, Barcelona, Spain, 2Bellvitge, Infectious Diseases, Barcelona, Spain, 3Hospital Sant Pau, Medicina Interna,
Barcelona, Spain, 4Fundacio IrsiCaixa, HIV, Barcelona, Spain, 5Hospital Vall d´Hebron, Infectious Diseases, Barcelona, Spain, 6Hospital de Elche, Medicine,
Elche, Spain, 7Hospital del Mar, Infectious Diseases, Barcelona, Spain, 8Gregorio Marañon, Medicina, Madrid, Spain, 9Hospital Principe de Asturias, Medicina,
Madrid, Spain, 10Clinico San Carlos, Medicina, Madrid, Spain, 11Hospital Clinic Universitari, Pharmacology, Barcelona, Spain, 12Hospital Clinic Universitari,
Biostatistics, Barcelona, Spain 13 Hospital Joan XXIII, Tarragona 14 Hospital Son Dureta. Palma de Mallorca. 15 Hospital de Granollers. 16 Hospital de Calella.17
Mutua de Tarrasa. 18 Hospital de Hospitalet. 19 Consorci Sanitari de Tarrasa.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention Sydney, Australia, July 22-26, 2007
WEPEB117LB
2
Background ATV is a potent, well-tolerated, once-daily (QD) protease
inhibitor (PI) extensively studied in treatment-naive and -experienced patients
The SWAN study (BMS 097)1 demonstrated that switching from PI ± RTV-containing regimens to an unboosted ATV-containing regimen maintained virologic suppression with improvement in plasma lipids through 48 weeks in patients without previous failures to PI contaning regimens
However, there are limited data available on the utility of switching virologically suppressed patients from LPV/r-based regimens to a different boosted PI such as ATV/r including those with previous failures to PI containing regimens or PI associated mutations
1Gatell et al. Clin Infect Dis 2007
3
Objective
To assess the safety and efficacy of ATV/r based HAART in virologically suppressed patients receiving a LPV/r contaning regimen including patients with previous failures (< 3) to PI regimens or history of having PI associated mutations (< 5) prior to starting the LPV/r-based regimen.
4
Final Analysis, Week 96
Switch to ATV/r QD†
(N = 121) BaselineContinue LPV/r BID*
(N = 127)
* LPV/r 400/100 mg BID capsules then tablets when available + unchanged NRTI backbone.† ATV/r 300/100 mg QD + unchanged NRTI backbone.
Study Population (N = 265) Stable LPV/r-based Regimen for > 6 months (VL < 200)
< 3 Previous Virologic Failures While on PI-based HAART and < 5 PI-associated mutations
The study was conducted in Spain
Primary Analysis, Week 48
1:1 Randomization
Study Design
5
Primary end-point
– The proportion of patients with treatment failure for any reason through Week 48• Includes virologic rebound (> 200 cp/mL),
discontinuation of study therapy or lost to follow-up, progression to a new CDC event or death.
• Non-inferiority study. Upper limit of 95% CI of estimated difference < 12.5%.
6
Secondary end-points
– The proportion of patients with virologic
rebound at or prior to Week 48
• Confirmed on-study HIV RNA ≥ 200 copies/mL or
last on-study HIV RNA ≥ 200 copies/mL followed
by discontinuation
– Time to treatment failure and to virologic
failure
– Safety
– Evolution of fasting plasma lipids
7
8
GeneralATV/r LPV/r
N = 121 N = 127
Median Age, y 42 43
Gender, N (%)
Male 97 (80) 100 (79)
Risk group, N (%)
Heterosexual trans. 45(37) 40(31)
MSM 27(22) 41 (32)
IDUs 39 (32) 37 (29)
Other 10 (8) 9 (7)
AIDS, N (%) 48 (40) 74 (57)
CD4 < 200, cell/ mm3 9(8) 12 (10)
Median CD4, cells/mm3 472 435
Baseline Characteristics
9
Laboratory
ATV/r LPV/r
N = 121 N = 127
Total chol > 240 mg/dl, N (%) 28 (23%) 26 (20%)
TG > 500 mg/dl, N (%) 4 (3%) 13 (10%)*
LDL-c > 130 mg/dl, N (%) 24 (20%) 25 (20%)
HDL-c < 40 mg/dl, N (%) 19 (16%) 27 (21%)
ALT > 40, N (%) 28 (24%) 22 (18%)
AST > 40, N (%) 20 (21%) 24 (23%)
ALT or AST > 40, N (%) 34 (28%) 33 (26%)
Baseline Characteristics
* P=0.023
10
ARV TherapyATV/r LPV/r
N = 121 N = 127ARV exposure, yr. 5.1 5.4
1st. ARV regimen, N (%) 17 (14) 19 (15)
1st. ARV regimen with PI, N (%) 36 (30) 42 (33)
Previous mono/bi therapy, N (%) 47 (39) 48 (38)
Current ZDV+3TC, N (%) 12 (10) 20 (16)
Current TDF+3TC, N (%) 24 (20) 22 (17)
Current TDF+ddI, N (%) 21 (17) 12 (9)
Current ddI+3TC, N (%) 8 (7) 9 (7)
Previous PI failures (>=1), N (%) 25 (21) 25 (20)
History of Previous PI mutations
>=1, N (%) 43 (36) 41 (32)
>=1 major, N (%) 17 (14) 13 (10)
None, N (%) 3 (1) 9 (7)
Not tested, N (%) 75 (63) 77 (61)
Baseline Characteristics
11
Patient Disposition at month 12
Pacientes enrolled(n=265)
Assigned to continue with LPV/r (n=127) #
Assigned to switch to ATV/r (n=121) #
Continuing assigned therapy 109† (86%)Discontinued 18 (14%)
Adverse events 6Death 1 *Virological failure 1Lost to follow-up 6Patient decission 2Other 2
Continuing assigned therapy 105† (86%)Discontinued 17 (14%)
Adverse events 6Death 0Virological failure 1Lost to follow-up 7Patient decission 0Other 2
† 5 subjects with virological failure † 7 subjects with virological failure
* Hepatic encephalopaty # 11 additional patients not eligible # 6 additional patients not eligible
12
Virologic Failure (≥ 200 c/mL)Treatment Failure
ATV/r LPV/r
0
5
10
15
20
25
30
p = NS
17%
20%
21/121 25/127
Difference Estimate (95% CI) -2.3% (–12%, 8%) –1.3% (–7.7%, 4.8%)
Treatment Failure and Virologic Failure (≥ 200 c/mL) through month 12
0
5
10
15
20
25
30
p = NS
5%6%
6/121 8/127
Pro
po
rtio
n o
f p
atie
nts
Pro
po
rtio
n o
f p
atie
nts
13
Time to treatment failure
14
Time to virological failure
p=0.609, long rank test
P=0.5P=0.5
15
ATV/r (n=121) LPV/r (127)
N 6 8
Previous PI failures 2 4Previous PI mutations 6 1Previous PI major mutations 2 1High baseline risk (*) 5 5
Reported lack of adherence 0 4Continue with same cART 5 7Virological response at 12 mo. 3 4
* Previous >= 1 PI failure or >= 3 PI mutations or >= 1 major PI mutation
Virological failures through month 12
16
CD4 Changes
Median changes from baseline in CD4 cell count were similar beteween groups: +26 cells/mm3 (ATV/r) and +51 cells/mm3 (LPV/r) at month 12 (p=0.2)
541
435
495
472
400
450
500
550
600
BL m1 m4 m8 m12
CD
4 co
un
t (c
ells
/mL
)
LPV/r
ATV/r
17
Adverse Events through month 12.
Adverse Events leading to discontinuation
ATV/r LPV/rN = 121N (%)
N = 127N (%)
Total 6 (5) 6 (5)GI-related 1 (1) 2 (2)
CNS 1 (1) 0 (0)
Liver 1 (1) # 0 (0)
Metabolic-related 1 (1) 4 (4)
Hyperbilirubin/Jaundice 2 (2) 0 (0)
* Hepatic encephalopaty; # ALT 113, AST 90
Death 0 (0) 1 (1) *Any AE 74 (58) 63 (52)
18
LAB Abnormalities
Liver Function Abnormalities (ALT/AST > 200; bilirrubin > 5)
ATV/r N = 121
LPV/rN = 127
ALT 2% 1%
AST 2 % 2%
ALT or AST 4% 2%
Total bilirubin 5% 2%
Liver Function Abnormalities (ALT/AST > 200 ) when ALT or AST
were > 40 at baseline
ATV/r N = 34
LPV/rN = 33
ALT 9 % 6%
AST 9 % 6%
ALT or AST 12% 6%
19
Fasting LIPIDS. Median values and Changes From Baseline in Lipid Parameters at month 12
Fasting Lipids
ATV/r LPV/rP
valueBL m12Change mg/dL
BL m12Change mg/dL
TG, mg/dL 181 145 -51 (-29%) 191 202 -3 (-1%) <0.0001
Total Chol, mg/dL 202 193 -19 (-9%) 205 207 -4 (-2%) <0.0001
LDL-c, mg/dL 107 111 -8 (-7%) 111 111 -2 (-3%) 0.163
HDL-c, mg/dL 50 46 -3 (-6%) 49 46 -2 (-3%) 0.375
20
CHANGE IN MEDIAN FASTING PLASMA LIPIDS
-60
-40
-20
0
20
Lop/r Ata/ r Lop/ r Ata/ r Lop/ r Ata/ r Lop/ r Ata/ r
TG Cholest LDL HDL
P<0.0001 P<0.0001
mg
/dl
(Mo
. 12
- M
o.
0)
21LIPIDS. Percentage above NCEP treatment recommendations at baseline and through month 12.
ATV/rN=121
LPV/rN=127
BL Mo 12 Change BL Mo 12 Change
TG m12 > 500 mg/dL 3% 4% +1% 10% 17% +7%
Total Chol > 240 mg/dL 23% 20% -3% 20% 26% +6%
LDL > 130 mg/dL 20% 25% +5% 20% 30% +10%
HDL < 40 mg/dL 16% 32% +16% 21% 29% +8%
No significant changes were obseved in Lipid Lowering Agents (LLA) usage during the follow-up in both arms.
22
Conclusions
Switching to ATV/r in virologically suppressed patients who were receiving a LPV/r containing HAART provided comparable efficacy and safety profile with improved lipid parameters.
23
ATAZIP Study GroupHOSPITAL CLINICBARCELONAJ. MallolasJ.M. GatellJ. PichE. de LazzariE. MartínezA. MilinkovicA. CrucetaH. AgellJ.A. Arnaiz
HOSPITAL BELLVITGEHOSPITALETD. PodzamczerE. FerrerG. Leibenger
HOSPITAL SANT PAUBARCELONAP. DomingoM. GutiérrezerrerG. Mateo
HOSPITAL GERMANS TRIAS I PUJOLBADALONAB. ClotetP. EcheverriaC. Alcalde
HOSPITAL VALL D’HEBRÓNBARCELONAE. RiberaS. Villar
HOSPITAL ELCHEALICANTEF. GutiérrezM. MasiáE. Bernal
HOSPITAL MARBARCELONAH. KnobelA. GonzálezG. Mestre
HOSPITAL GREGORIO MARAÑÓN MADRIDJ. CosínM. SánchezM. RamírezI. Gutiérrez
HOSPITAL PRINCIPEASTURIAS MADRIDJ.A. ArranzJ. SanzE. Casas
HOSPITAL CLÍNICOSAN CARLOS MADRIDV. RocaJ. VergasM.J. Téllez
HOSPITAL JOAN XXIII TARRAGONA
F. VidalJ. PeraireM. Saumoy
HOSPITAL SON DURETAPALMA MALLORCAM. PeñarandaJ. Murillas
HOSPITAL GRANOLLERS GRANOLLERS
E. PedrolE. Deig
HOSPITAL CALELLACALELLAJ.M. LlibreS. Valero
HOSPITAL MUTUA TERRASSA
TERRASSAD. DalmauM. Cairó
HOSPITAL L’HOSPITALETHOSPITALETI. García
HOSPITAL TERRASSATERRASSAM. Aranda